Alluvi, previously BI 4744, presents a significant breakthrough in obesity treatment. This dual agonist targeting both glucagon-like peptide-1 and GIP receptors demonstrates compelling results in clinical assessments, https://alluvi-peptides473532.infantblog.com/profile